They will then compare current legislation with the practices that are due to develop stem cells in the near future, more especially in the research infrastructures to highlight the deficiencies and propose sustainable solutions. Special interest will also be paid to emerging such as "cell tourism" or the use of unproved therapies. For example, in some European countries doctors propose to use regenerative medicine techniques which have yet to be scientifically validated and which do not meet the safety criteria imposed by both French and European legislation.
The ultimate objective is to make recommendations to the European Commission so as to facilitate the use of stem cells for clinical purposes in a stabilised legal context. Thus the results of the project will enable innovation in research and help the European to implement specific legislation in this field.
The 4 phases of the EUCelLEX Project:
1. Information gathering on the legal implementation of the directive on tissues and cells, with the focus on current European legislation and the regulations set forth at national level.
2. Integration of this knowledge into a wider analytical context covering the entire field, focusing on stem cells and the cord blood banks.
3. Make an in-depth analysis of the legislation, the literature, case law and the gathering of opinions on the various ethical aspects.
4. Create tools for the participation of the professional people involved and he key players in the questions raised by the use of stem cells.
The research partners in the EUCelLEX consortium, based throughout Europe and in Canada, will use their scientific, legal and ethical skills to highlight the issues raised by the use of stem cells for the medicine of tomorrow.
|Contact: Emmanuelle Rial-Sebbag|
INSERM (Institut national de la sant et de la recherche mdicale)